Guselkumab 100 mg, administered every 4 or 8 weeks, led to significant improvements in signs and symptoms of active psoriatic arthritis (PsA) in patients with inadequate response to only one prior TNF ...

The response time to tumour necrosis factor (TNF) inhibitors in patients with psoriatic arthritis is influenced by the location of the affected joint. The shoulder and elbow joints exhibit higher ...

BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...

Early treatment of pediatric Crohn's disease with anti-tumor necrosis factor medications can substantially reduce the risk of perianal fistulas, a particularly debilitating complication of Crohn's ...

Exposure to TNF inhibitors was associated with a reduced risk for new-onset depression among patients with ankylosing spondylitis. Tumor necrosis factor (TNF) inhibitor therapy is associated with a ...

Drug retention was similar with second-line IL-17 inhibitors vs TNF inhibitors in patients with axial spondyloarthritis who discontinued their initial TNF inhibitor, though IL-17 inhibitors showed ...

More than half of patients with treatment-resistant hidradenitis suppurativa achieved a 55% improvement in their disease after initiating golimumab, a tumor necrosis factor inhibitor, according to a ...

Children with nonsystemic juvenile idiopathic arthritis who initiated TNF inhibitors when aged 2 years or less showed significant and sustained improvements in disease activity. Early initiation of ...

Patients with rheumatoid arthritis (RA) have longer persistence with upadacitinib than tumor necrosis factor inhibitors (TNFi ...

ORLANDO -- Major cardiovascular event risk in patients with inflammatory bowel disease (IBD) was no greater with Janus kinase (JAK) inhibitors than with tumor necrosis factor (TNF) inhibitors, ...